by Kyle Becker, Becker News:
Project Veritas claims to have obtained internal documents from an employee at Google showing the company’s scramble to do public relations fallout for Pfizer, Inc.
The internal documentation was shared on Twitter on Monday:
TRUTH LIVES on at https://sgtreport.tv/
BREAKING: @YouTube Insider leaks “Urgent Guidance” document sent to employees on how to handle the Project Veritas @pfizer #DirectedEvolution video “Effective immediately as of 27 January 2023”
“Violates the COVID-19 misinformation policy” pic.twitter.com/lC7OJajs8a
— Project Veritas (@Project_Veritas) January 30, 2023
The document reads “URGENT GUIDANCE: Project Veritas video on the Pfizer vaccine, 27 Jan 2023.” It states:
WHAT: A clip unloaded by Project Veritas featuring a Pfizer official is rapidly spreading on the platform. The video, when uploaded in its entiretly contains a timestamp that violates the COVID-19 Vaccine Misinformation policy for making a categorical claim that COVID-19 vaccines are ineffective, and should therefore be removed unless it contains sufficient EDSA/CRC.
The document than proceeds to direct employees to “check the 4 corners and metadata for EDSA that clearly contradicts, refutes or countervails the violative timestamp without additional promotion (generalization, aggregation, repetition, affirmation).”
It then states to “Action the content” with a “STRIKE” if “no sufficient CRC is present in the 4 corners, title or description.”
It is important that we remove violative reuploads of this content as it spreads harmful misinformation about approved vaccines against COVID-19,” the directive adds.
The guidance is directed at “All agents working Medical Misinfo Queues” and “Rapid Response.” The guidance is dated effective as of 27, January 2023.
It is critical to note that Google, much like Pfizer, does not deny that Jordon Triston Walker is a “Pfizer official.”
CLICK HERE TO READ MORE FROM BECKER NEWS
This is what Pfizer had to say about the video in a statement on its official company website:
Allegations have recently been made related to gain of function and directed evolution research at Pfizer and the company would like to set the record straight.
In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research. Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. This work is undertaken once a new variant of concern has been identified by public health authorities. This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern. We then make this data available through peer reviewed scientific journals and use it as one of the steps to determine whether a vaccine update is required.
Pfizer, after this non-specific denial written in passive voice, followed by shifting time windows, then pivots to discussing Paxlovid.
In addition, to meet U.S. and global regulatory requirements for our oral treatment, PAXLOVID™, Pfizer undertakes in vitro work (e.g., in a laboratory culture dish) to identify potential resistance mutations to nirmatrelvir, one of PAXLOVID’s two components. With a naturally evolving virus, it is important to routinely assess the activity of an antiviral. Most of this work is conducted using computer simulations or mutations of the main protease–a non-infectious part of the virus. In a limited number of cases when a full virus does not contain any known gain of function mutations, such virus may be engineered to enable the assessment of antiviral activity in cells. In addition, in vitro resistance selection experiments are undertaken in cells incubated with SARS-CoV-2 and nirmatrelvir in our secure Biosafety level 3 (BSL3) laboratory to assess whether the main protease can mutate to yield resistant strains of the virus. It is important to note that these studies are required by U.S. and global regulators for all antiviral products and are carried out by many companies and academic institutions in the U.S. and around the world.
